Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

NEXT STORY
Teladoc Health Issues Inaugural Corporate Social Responsibility Report
PREV STORY
Medical Device Testing Market to Reach $12.5 Billion by 2027, Growing at a CAGR of 4.7% From 2020 With COVID-19 Impact – Meticulous Research® Analysis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a ...

author_avatar
NASDAQ Market News

Sera Prognostics Completes $100 Million Series E Financing

author_avatar
NASDAQ Market News

Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock

author_avatar
NASDAQ Market News